Virginia Commonwealth University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Virginia Commonwealth University sits in the top decile of US sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count).

558 total trials 77 currently recruiting 380 completed early-phase tilt top decile by trial count

Virginia Commonwealth University: 558 sponsored US clinical trials, 77 recruiting.

Virginia Commonwealth University sponsors 558 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 380 completed. 35 of these trials are in Phase 3-4 (later-stage) and 145 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 8 trials.

Top-decile sponsor footprint

Virginia Commonwealth University ranks in the top decile of sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 45/100

380 of 462 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

558 total, page 11 of 12

COMPLETED NA

Use of Laryngeal Mask Airway in Pediatric Adenotonsillectomy

NCT01141660

COMPLETED NA

Barriers to Effective Weight Loss in Overweight Adolescents

NCT00562263

COMPLETED NA

An Interactive Preventive Health Record (IPHR) to Promote Patient-Centered Preventive Care

NCT00589173

COMPLETED

Observational Endothelin and Markers of Cellular Apoptosis In CSF Head Injury

NCT00498498

COMPLETED

Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV

NCT00575757

TERMINATED Phase 2

Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women

NCT00201448

COMPLETED Phase 1

Prevention of Self-care Deterioration in Early Adolescents With Diabetes

NCT00890331

COMPLETED Phase 2

Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury

NCT00580970

COMPLETED

Short Term Outcomes From Minimally Invasive Surgery for the Treatment of Atrial Fibrillation

NCT00571597

TERMINATED Phase 3

Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases

NCT00581113

COMPLETED NA

Insulin and the Polycystic Ovary Syndrome--Weight Reduction Study

NCT00436865

TERMINATED NA

Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents

NCT00369967

TERMINATED Phase 3

Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding

NCT00409084

TERMINATED

Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation

NCT00615719

TERMINATED Phase 1

Extrapleural Intercostal Catheter vs. Thoracic Epidural for Thoracotomy Pain

NCT00373633

COMPLETED

Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children

NCT00308906

COMPLETED NA

A Comprehensive Practice-Friendly Model for Promoting Healthy Behaviors

NCT00292968

TERMINATED Phase 1

Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable NSCLC

NCT00692380

COMPLETED NA

Tolerability and Efficacy of Depakote-extended Release in the Elderly

NCT00318929

COMPLETED

New Strategies for Non-invasive Detection of Chronic Allograft Nephropathy

NCT00283348

COMPLETED NA

Insulin and Polycystic Ovary Syndrome

NCT00683774

COMPLETED NA

Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C

NCT00252642

TERMINATED Phase 4

Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)

NCT00682890

COMPLETED NA

Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3

NCT00390559

COMPLETED Phase 2

Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer

NCT00107484

COMPLETED Phase 3

Development of a Breath Test for Monitoring Patients With Liver Disease

NCT00244569

COMPLETED Phase 4

A Peri-intubation Oral Intervention to Reduce Oral Flora and VAP

NCT00248300

COMPLETED Phase 4

Oral Contraceptives in the Metabolic Syndrome

NCT00205504

TERMINATED Phase 4

Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees

NCT00249379

COMPLETED Early Phase 1

Pilot Study of 18F Fluoropaclitaxel (FPAC)

NCT00572598

TERMINATED Phase 3

Botox for Non-surgical Lateral Release in Patellofemoral Pain

NCT00496964

COMPLETED Phase 4

Pharmacological Intervention in Depression After Traumatic Brain Injury

NCT00205491

COMPLETED

A Prospective Study of Natural History of Pancreatitis

NCT00685087

COMPLETED Phase 1

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

NCT00580320

COMPLETED NA

Study of Effects of Sutures on Results of Palate Surgery for Obstructive Sleep Apnea

NCT00205543

COMPLETED

HIV-HCV Coinfection: Impact of Immune Dysfunction

NCT00575315

COMPLETED

Histamine Pharmacogenetics in Children With Atopic Dermatitis

NCT00277433

COMPLETED Phase 1

Barriers to Treatment in Obese Adolescents

NCT00167830

COMPLETED NA

Checking Smoking Status as a Routine Vital Sign: A Cluster-Randomized Trial of Its Effect on Cessation Counseling

NCT00245323

COMPLETED Phase 1

Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

NCT00064285

COMPLETED

Transplant Patient Registry of Liver, Kidney and/or Pancreas

NCT00238693

COMPLETED NA

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

NCT00243321

COMPLETED

Evaluation of an Intervention Model for Family Crisis and Support

NCT00205530

COMPLETED NA

Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea

NCT00310323

COMPLETED

Acute Cognitive and Neurobehavioral Intervention: Efficacy Evaluation

NCT00205569

COMPLETED Phase 3

Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection

NCT00248339

COMPLETED Phase 2

Strategies to Prevent Pneumonia (SToP Pneumonia)

NCT00234598

COMPLETED Phase 2

Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia

NCT00017342

COMPLETED Phase 4

Treatment of Alcohol Withdrawal in Hospital Patients

NCT00249366

TERMINATED Phase 2

Oral Administration of DCI to Women With PCOS

NCT00497653

← Previous Page 11 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 80
Phase 2 65
Phase 3 13
Phase 4 22

What is open in the Virginia Commonwealth University pipeline

77 recruiting of 558 indexed (14% open); 380 completed (68%).

Phase mix: 35 late (III/IV) vs 145 early (I/II) (early-phase heavy).

Top condition: Obesity (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Virginia Commonwealth University: open-pipeline peers nationwide

Peers matched on 558 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Virginia Commonwealth University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 5%10%15%20%25% Total trials Recruiting share Virginia Commonwealth UniversityAmgenMerck Sharp & DohmeUniversity of Maryland, BaltimoreOhio State UniversityLindenwood UniversityBeiGeneReproductive Medicine Associates of New JerseyUniversity of Cincinnati
Virginia Commonwealth University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Virginia Commonwealth University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 558 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

What to do with this Virginia Commonwealth University page

558 registered trials is a research-attention snapshot, not an endorsement of Virginia Commonwealth University or any single study.

  • 77 of Virginia Commonwealth University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Virginia Commonwealth University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Virginia Commonwealth University pipeline card: 558 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.